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GETTERAL IlrTTRODU~TION 
Thesis organization 
My thesis includes a general introduction about the objectives, hypothesis, specific 
aims, and significance of our research, followed by a review of literature, a manuscript, and 
general conclusions. References for chapters 1 and 2 appear at the end of the review of 
literature, whereas references for chapter 3 appear at the end of the manuscript. 
~b j ectives 
The purpose of this study was to determine whether soy protein components, 
isoflavones and phytate, would reduce the risk of cardiovascular disease {CVD) in 
postmenopausal women. 
Hypothesis 
Soy protein components will reduce the risk of CVD in postmenopausal women, 
specifically that isoflavones will favorably alter blood lipid concentrations and that phytate 
will decrease oxidative stress indices. 
SpeC1f1C AIInS 
To determine the effect of phytate and isoflavones from 40 g of soy protein on CVD 
risk as reflected by circulating lipids and oxidative stress indices. 
Significance of Study 
Men are usually at higher risk of developing CVD than women; however, after 
menopause the risk for women becomes similar to that of men. The lack of estrogen affects 
antioxidant status, as well as lipid and lipoprotein concentrations {Goudev et al. 2000), both 
of which have been implicated in the pathogenesis of CVD {Saito et al. 2003; Cooke et al. 
2003). Evidence indicates that oxidative stress increases and oxidative defenses decrease 
after menopause, contributing to the rise in CVD. 
Soy protein consumption has been shown to significantly decrease ser~~m 
concentrations of TC, LDL-cholesterol, and triacylglycerols (TG) (Vigna et al. 2000; 
Scheiber et al. 2001). This cholesterol-lowering activity is generally attributed to the 
isoflavones in soy. In addition, soy isoflavones may also possess antioxidant properties, 
protecting against oxidation of LDL (Jenkins et al. 2000a). 
Phytate, another component of soy protein, was originally considered an anti-nutrient. 
However, phytate has been shown to have some health benefits, including lipid-Lowering 
activities (Jariwalla et al. 1990; Klevay 1977). Because of its binding capacity to iron, 
phy~tate makes iron unavailable to participate in the Fention reaction for hydroxyl radical 
formation (Rao et al. 1991), and thus may prevent oxidative stress, such as atherosclerotic 
lesion formation and lipid peroxidation {loo and Godin 1991; Porres et al. 1999). 
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REVIEW OF LITERATURE 
Diseases Associated with Aging 
Aging is associated with gradual biochemical, physiologic, and fiunctional changes. It 
may be defined as a cumulative process of damaged body constituents that are not repaired or 
renewed, leading to malfunction of physiological processes, resulting in death due to internal 
or external stresses (Coto et al. 1995). Cellular proliferation, declining rates of 
deoxyribonucleic acid (DNA) repair, free radical damage, lower rates of protein synthesis, 
and immunologic breakdown are some additional examples of possible alterations that aging 
individuals experience. The main underlying cause of these physiologic changes is cellular 
aging, which is the gradual decrease in the ability of a cell to maintain homeostasis. This 
deterioration in cellular homeostasis is associated with an accumulation of abnormal and 
oxidatively altered proteins in cells (Vittorini et al. 1999). While there are protective systems 
to compensate for cellular damage, these defense mechanisms themselves may be 
compromised. Therefore, aged individuals potentially face many health issues, such as 
neurodegenerative diseases, CVD, and osteoporosis. However, my thesis focuses mainly on 
CVD and is discussed below in detail, 
cardiovascular Disease 
Cardiovascular disease is one of the leading causes of death among middle-aged men 
and postmenopausal women. The major underlying cause of CVD is atherosclerosis, aslow, 
progressive disease in which lesions of plaque build up in the arterial wall as a result of 
intimal injury. Cane of the factors that cause injury is an alteration in blood lipids. Stevenson 
et al. (1993) found that TC, LDL-C, and TG concentrations had positive associations with 
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age, while a significant negative association was observed between age and high-density 
lipoprotein cholesterol (HDL-C) concentration. 
Risk Factors 
There are many contributing factors to CVD, some of which are nonmodifiable. 
However, most are modifiable with dietary intervention, exercise, medication, or a 
combination of therapies. 
1Vonmodi~able 
Age is a strong contributor to the CVD risk. The rate of cardiovascular morbid events 
dramatically increases after the age of 70 (Nevin and Pharr 2002), because activity levels 
decrease and cholesterol concentrations rise. Also, coronary artery disease (CAD) is very 
dependent on age in women. 
Gender also has an affect on disease risk, whereby men are usually at higher risk of 
developing CVD than women. After menopause, the risk for women becomes similar to that 
of men. In postmenopausal women, the lack of estrogen affects antioxidant systems, as well 
as lipid and lipoprotein concentrations, leading to increased risk of CVD (Goudev et a1. 
2000). The absence of estrogen also causes adverse changes in vessel walls, as well as 
unfavorable alterations in prostacyclins, steroids, lipoprotein(a}, and growth factors. These 
factors cause postmenopausal women to experience enhanced cardiovascular stress responses 
compared to men and premenopausal women (Bairey-Merz et al. 1998). This greater 
reactivity could augment the development of atherosclerosis, thrombosis, and elicit a 
myocardial infarction. Additionally, these menopause-related effects appear to be 
independent of the aging process (Stevenson et al. 1993}. Few women recognize their 
susceptibility to heart disease, and thus delay the identification of disease, making the 
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prognosis of CVD much less favorable than it is for men. Therefore, many women may have 
fairly advanced disease by the time a diagnosis is even established (Lewis 2002; 'V~enger 
1997). 
A family history of dyslipidemia {elevated TC, LDL-C and TG, low HDL-C) is 
another strong risk factor far developing CVD. For example, dyslipidemia is highly 
inheritable and contributes strongly to the development and progression of atherosclerosis. 
Individuals with genetic disorders, such as familial hypercholesterolemia, in which there is a 
defect in LDL receptor function, are at high risk for early atherosclerosis and myocardial 
infarction (Brook et al. 1989). Although heterozygotes, respond well to medication and 
dietary intervention, individuals who are homozygous do not usually live beyond twenty 
years of age (Sprecher et al. 1984). 
Modi cable 
Traditional risk factors for CVD include elevated blood pressure, hypertension, 
dyslipidemia, smoking, and diabetes mellitus, all of which are amenable to change (Saito et 
al. 2003}. Other modifiable factors, such as poor diet, impairment of glucose tolerance, 
obesity, and physical inactivity are interrelated and also contribute to the disease. In 
addition, several new markers of risk have been suggested for use in screening to better 
identify patients at high risk for cardiovascular events. They include elevated circulating c-
reactive protein (CRP), homocysteine, excess iron, and oxidative stress. Circulating 
concentrations of apolipoprotein A-I, apolipoprotein B-100, lipoprotein(a), and interleukin-6 
may also be possible predictors of lesions that lead to the development of CVD and 
cardiovascular events. Because CVD is still the leading cause of death in men and women, 
there is an ongoing need to define the most powerful predictors. It is also important to take 
into consideration that various cardiovascular factors may not be independent of one another, 
and may have direct or indirect effects on CVD (Saito et al. 2003}. My thesis will mainly 
focus on the risk associated with unfavorable lipid concentrations, elevated homocysteine 
and c-reactive protein concentrations, oxidative stress, and iron excess. 
Lipid Profile 
Lipids play many important physiologic roles. Of most importance is the role of 
cholesterol in membrane structure and function and the role of lipids in storing energy in 
adipocytes. Adipose tissue provides a cushion to protect organs and bones from injury. 
Serum cholesterol and TG concentrations are homeostatically controlled to meet these needs, 
and the body generally produces the amount required. However, the Western diet provides 
an abundance of energy and fat, particularly saturated fat, which generally contributes to high 
cholesterol concentrations. 
Alterations in blood lipids, such as increased LDL-C and TG, as we11 as decreased 
HDL-C, are all risk factors for CVD. Together, they aid in the formation of atheromatous 
lesions, which ultimately cause stenosis or occlusion of the arterial lumen (Saito et al. 2003). 
Numerous studies have indicated that LDL-C concentration should be considered the primary 
target in the assessment of CVD risk, but HDL-C may also be a critical factor in risk 
assessment. Because low HDL-C is associated with various other CVD risk factors, 
particularly cigarette smoking, obesity, and elevated TG, it follows that HDL-C may possibly 
be a marker when these potential causal variables are present. An eight-year follow-up study 
on men and women >_3 0 years of age revealed that HDL-C was inversely related to CVD and 
CAD mortality (Jacobs et al. 1990). In a more recent study, Lemieux et al. (2001) performed 
a metabolic profile (family history, history of smoking, diabetes mellitus, blood pressure, 
height and weight, lipid and lipoprotein profile, and electrocardiogram) in 2103 middle-aged 
men and observed significant differences in average TC/HDL-C ratios among the TG textiles, 
as well as elevated TC/HDL-C ratios among the overweight, hyperinsulinemic, and 
hypertriglyceridemic individuals. For these reasons, cholesterol and lipoprotein 
concentrations are essential in assessing the risk for CVD. 
Homocysteine 
Homocysteine is a naturally occurring, sulfur-containing amino acid produces from 
methionine. Methionine can also be regenerated from homocysteine in a reaction that is 
dependent on vitamin B 12 and folate. The normal plasma concentration in healthy 
individuals is approximately 10 µmol/L (Hoffer et al. 2001). However, this concentration is 
greatly influenced by age, gender, and medication, as well as genetic, nutritional, and 
pathologic factors. Plasma homocysteine increases with age and is higher in men than in 
women (Warren 2002). Additionally, premenopausal women have lower plasma 
homocysteine than postmenopausal women, and estrogen therapy (ET} appears to decrease 
concentrations (De Leo et al. 2000), suggesting that plasma homocysteine may also be 
related to estrogen status. tither major lifestyle determinants of plasma homocysteine 
include coffee consumption, smoking (I~Iygard et al. 1998), and end-stage renal disease 
(Hoffer et al. 2001). 
Homocysteine concentrations are inversely related to concentrations of vitamins B6, 
B 12, and folate. A deficiency in one or a combination of these nutrients can lead to 
hyperhomocysteinemia. This elevated plasma homocysteine concentration may significantly 
increase the risk of CAD and stroke and is thought to be an independent risk factor for CVD 
(Bautista et al. 2002). Stampfer et al. (1992) assessed this association in men and found that 
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moderately high plasma homocysteine was, in fact, associated with subsequent risk of 
myocardial infarction, independent of other coronary risk factors. S1mllarly, Ridker et al, 
(1999) reported that elevated homocysteine, independent of several other cardiovascular risk 
factors, moderately increased three-year risk of CVD in postmenopausal women. Similarly, 
in men and women <~0 years of age, an increased plasma total homocysteine concentration 
conferred an independent risk of vascular disease, similar to that of smoking or 
hyperlipidemia Graham et al. 1997). In addition to being a secondary consequence of Bb, 
B 12, and folate deficiency, very high plasma homocysteine also results from a rare genetic 
disorder of impaired homocysteine metabolism resulting in homocysteinuria. A 
characteristic feature of this condition is high circulating homocysteine concentrations, as 
well as severe, premature arteriosclerosis (Stampfer et al. 1992) and osteoporosis (Lubec et 
al. 1990, 
There are many possibilities to explain the relationship between homocysteine and 
CVD. A widely researched mechanism is the involvement of homocysteine in oxidative 
damage. ~Iomocysteine exerts toxicity on endothelial cells by increasing hydrogen peroxide 
(H2O2) production, causing stress on antioxidant defense systems, and promoting lipid 
peraxidation (Huang et a1.2001). As a consequence, blood vessels lose their elasticity and 
ability to dilate, resulting in greater intimal injury (warren 2002). Calcium, cholesterol, and 
collagen then adhere to the sites of intimal injury and form atherosclerotic plaques (V~arren 
2002). Thus, by damaging the endothelial lining of vessels, homocysteine contributes to 
atherosclerotic plaque development. Tofler et al. (2002) observed another passible 
mechanism, in that elevated homocysteine concentrations were lvlked to a decrease in 
fibrinolytic potential, thereby suggesting a prothrombotic effect. By reducing the production 
of nitric oxide (130) and prostacyclin, homocysteine interferes with the platelet-endothelium 
interaction. Also, by enhancing endothelial factor V activity and reducing the activity of 
thrombomodulin, homocysteine promotes clotting (De Leo et al. 2000). Elevated 
homocysteine has also been shown to stimulate the proliferation of vascular smooth muscle 
cells and impair endothelial-dependent vasodilatation (Tofler et al. 2002), thus suggesting 
another mechanism for the effect of homocysteine on CVD. 
C-Reactive Protein 
Evidence from recent studies has shown that inflar~imation plays a strong role in the 
pathogenesis of atherosclerosis. Inflammatory components are believed to contribute greatly 
to instability and rupture of atheromatous plaque, thus causing atherothrambotic events 
(Saito et al. 2003). A variety of biomarkers have been shown to predict risk of future 
cardiovascular events, including interleukin-6 and cellular adhesion molecule (Ridker 2000. 
I-Iawever, mast attention has focused on CRP, an acute-phase protein and conlm.only assayed 
marker of inflammatory and infectious responses. The liver produces CRP in response to 
cytokines, particularly interleukin-~. C-reactive protein induces expression of cellular 
adhesion molecules and mediates LDL upt~~ke by macrophages (Ridker 2003). Circulating 
concentrations of CRP are stable within individuals aver long periods of time, thus reflecting 
the chronic nature of the inflammatory process (Saito et al. 2003). Also, compared to other 
circulating markers of inflar~~m.ation, CRP seems to have the mast consistent relation to CVD 
risk in a variety of clinical settings {Saito et al. 2003). 
A recent study examined healthy postmenopausal women over a period of three years 
to assess the risk of cardiovascular events associated with baseline concentrations of CRP 
and other n~.arkers of inflammation. The concentration of CRP was the most significant 
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predictor of risk for cardiovascular events, even in women with LDL-C concentrations below 
13 0 mgldL {Ridker et al. 2000). Another study found that minimally elevated serum CRP 
concentrations far at Least six years were associated with increased mortality from CVD 
among older women (Tice et al. 2003). Based on these results, CRP has been proposed as an 
independent risk factor for CVD, myocardial infarction, stroke, and vascular death, 
especially among those who have hyperlipidemia and/or a heightened infl~atory 
response. tTnfortunately, the mechanism and pathophysiology explaining the relationship 
between CRP and CVD is not known, It may be that CRP indirectly contributes to foam cell 
formation by promoting Leukocyte adhesion to endothelial ce11s, resulting in enhanced 
recruitment of monocytes to atherosclerotic plaques {Niessen and Hack 2003 ; Tice et al. 
2003). 
Aside from the current interest in the role of CRP as an independent predictor of 
CVD, there is controversy about its direct function. while many studies suggest that CRP is 
an independent risk factor for CVD, the association may partly reflect mutual associations 
with already established CVD risk factors. C-reactive protein is associated with various risk 
predictors of CVD, including fibrinogen, plasma viscosity, and white cell count, all of which 
(like CRP), are associated with reactions mediated by cytokines, such as interleukin-6 
(woodward et x1.2003), C-reactive protein was also significantly positively associated with 
body mass index, serum TC, and TG, but negatively associated with serum HDL-C 
(woodward et al. 2003). Hence, it may be that the role of CRP in the pathogenesis of CVD 
is through its association with the above hematological factors. Yet, no matter how it is 
associated with CVD, inflammatory markers, such as CRP, may improve CVD prediction 
when used in conjunction with traditional risk factors (Saito et al. 2003). 
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As a result, researchers have evaluated strategies for expanding the routine screening 
approach to include CRP (Ridker 2003). However, there are (imitations in that elevated CRP 
concentrations may not always be predictive of CVD risk. Far example, CRP concentrations 
increase rapidly in response to injury, infection, inflammatory stimuli, and other disease 
conditions. It is also a marker of biologic aging (Kushner 2001) and menopause (Woodward 
et al. 2003 ). In addition, Saito et a1. (2003) found that subjects treated for hypertension, 
diabetes mellitus, and CAD had increased CRP. Overweight adults may also have elevated 
CRP, largely due to adipose tissue and its ability to secrete interleukin-6 (Saito et x1.2003}. 
Other states in which minor CRP elevations have been reported include chronic fatigue, high 
protein diets, depressive symptoms, and mild viral infections (Kushner and Sehga12002). 
Additionally, CRP concentrations fluctuate substantially from day to day, which may lead to 
considerable misinterpretation in this inflammatory marker with respect to its association 
with CVD. 
Oxidative Stress 
In healthy individuals, there is a balance between pro-oxidants and antioxidant 
defenses. Antioxidants significantly delay or inhibit the oxidation of substrates, thus 
detoxifying harmful oxidants. The major intracellular antioxidant enzymes involved in 
removing free radicals are superoxide dismutase (SOD), glutathione peroxidase, catalase, and 
glutathione reductase. Extracellular factors include vitamins E and C. Additional 
entracellular antioxidants include albumin, which inhibits copper-stimulated peroxidation of 
erythrocyte membranes, and uric acid, which may scavenge singlet oxygen, peroxyl radicals, 
and hydroxyl radicals (•OH) (Chanarat 1992). Table 1 lists the major antioxidants that 
protect against free radical reactions. 
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Table 1. Antioxidant protection against free radical reactions in vivo ~ 
Intracellular Factors Extracellular Factors 
Superoxide dismutase (SOD) Ceruloplasmin 
Catalase Albumin 
Glutathione peroxidase Lactoferrin 
Methionine sulphoxide reductase Extracellular SOD 
Urate 
Vitamin C 
Vitamin E 
Hyaluronic acid 
' Chanaratet 1992 
Vitamin E is a poor antioxidant in the cytoplasm, but its antioxidant property is 
extremely useful when associated in the membrane (Gutteridge 1995). Because of its 
lipophilic characteristics, it protects membranes against lipid peroxidation by scavenging 
lipid peroxide. Vitamin C acts by scavenging H2O2, as well as the superoxide (02 •) and 
•OH (Chanarat 1992). Other antioxidant enzyme systems are involved in promoting the 
synthesis of various antioxidants and in preventing the actual formation of reactive oxygen 
species (ROS). 
Antioxidants combined may have an additive effect in protecting against oxidative 
stress. Goudev et al. (2000) found that acombined-antioxidant supplementation in 
postmenopausal women for 12 weeks inhibited free radical formation, and decreased serum 
concentrations of cellular adhesion molecules, which are markers of arterial wall 
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inflammation. Ultimately, antioxidants protect against excessive free radical generation and 
the consequences thereof (I~.ice-Evans 1995). They are present throughout the body, 
including in the interstitial fluid of the arterial wall, where lipoprotein oxidation is thought to 
occur (I~ontush and Beisiegel 1999). I-Ience, depletion of antioxidant capacity increases 
oxidative stress and damage. 
Table 2. Sources of reactive oxygen species-free radicals in humans 
Physical Biological 
Ionizing radiation vzflammation 
Ultraviolet Ischemia/reperfusion 
Endogenous sources 
Chemical 
Carcinogens/drugs 
Tobacco smoke 
Transition metals 
Iron 
Copper 
Okada 199+ 
A disruption in the balance between pro-oxidant and antioxidant systems in cells may 
be defined as oxidative stress, which has also been implicated in the pathogenesis of cancer, 
CVD, and many neurodegenerative conditions, including Alzheimer's disease, Huntington's 
disease, and Parkinson's disease (Cooke et al. 2003). Individuals are exposed to an array of 
exogenous sources of oxidative stress, including irradiation, drugs, and toxic, mutagenic, and 
carcinogenic chemicals. Oxidative stress may also originate from the diet or from normal 
physiological processes or pathological states. Table 2 lists various sources of oxidants. 
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Polyunsaturated fatty acids, proteins, DNA, and carbohydrates are all susceptible to 
attack by oxidants (Chanarat 1992}, and this damage accumulates with age (Packer 1995). 
fiver time, endogenously generated free radicals may cause cellular damage leading to 
gradual deterioration, dysfunction, and disease states associated with aging (Cooney and 
Mordan 1995). Figure 1 illustrates the potential consequences of such oxidative damage. 
Figure 1. Free Radical Damage 
Target Canseq uences 
.Proteins  ~; Cell Injury 
Lipid '""~-  LDL /► Atherosclerosis -~CVD 
oxidation Damage 
DNA 
Carbohydrates 
Mutation Cancer 
 ►Cell Dysfunction 
Free radicals are atoms or molecules that have one or more unpaired electron(s). The 
radicals originate from exogenous or endogenous sources and are generally unstable and very 
reactive. ~1~hile they are essential to many beneficial physiological processes, such as signal 
transduction and gene transcription (Fang et al. 2002), they also act as highly deleterious, 
cytotoxic oxidants if produced in excess of normal requirements (Rice-Evans 1995). The 
imbalance of electrons makes them highly reactive with other compounds, as we11 as with 
each other. Further, when defense mechanisms have been compromised, free radicals inflict 
damage throughout the cell and the surrounding tissue (Kilgore and Lucchesi 1995). Many 
chronic diseases are initiated by this oxidation of cellular components. Additionally, they 
may be related to the process of aging. 
~~ 
Table 3 displays the various ROS, including radical and non-radical forms. Reactive 
oxygen species formulate from exposure to chemicals, drugs, radiation, high oxygen, and 
normal physiological processes. The 0 2-• anion is produced when oxygen molecules react 
with catecholamines, as well as when electrons leak from the electron transport chain 
Table 3 . Reactive Oxygen and Nitrogen Species 1
Reactive Oxygen Species Reactive Nitrogen Species 
Radicals Non-radicals Radicals Non-radicals 
Superoxide 
Hydroxyl 
Hydroperoxyl 
Alkoxyl 
Peroxyl 
Ozone 
Singlet oxygen 
Hypochlorous acid 
Hydrogen peroxide 
Nitric oxide 
Nitrogen dioxide 
Nitrous acid 
Peroxynitrite 
Alkyl peroxynitrite 
1 From Groff and Dropper 2000 
in the mitochondria. It is a precursor for a number of ROS, including H2O2, the 
hydroperoxyl radical, and the hydrogen dioxyl radical. Superoxide dismutase eliminates 0 2-• 
radicals from cells before they elicit damage, but unfortunately, H2O2 is generated in the 
process. Hydrogen peroxide can be converted to water by glutathione peroxidase or catalase, 
but the rate of H2O2 production by SOD is much faster (Gutteridge 1995). Thus, H2O2 is 
available to react with still existing 0 2-• radicals to produce •OH, the most potent and 
reactive of the ROS. Damage by •OH is very site-specific and often produces products that 
cannot be regenerated by normal cellular metabolism. Unfortunately, this radical lacks a 
specific enzyme-based defense system to scavenge its existence (1Vlorris et al. 1995). The 
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singlet oxygen is an additional radical formed by the oxidation of other ROS, as well as from 
lipid peroxidation of membranes, enzymatic reactions, and photochemical reactions. 
Free radicals that contain nitrogen are identified as reactive nitrogen species (Table 
3). They are comprised of NO and nitrogen dioxide, which, similar to ROS, can also be 
converted to non-radicals, such as peroxynitrite. Nitric oxide is an enzymatically-generated 
free radical and is synthesized in a variety of cells. It is one of the most widespread signaling 
molecules and participates in virtually every cellular and organ function (Fang et al. 2002). 
It is extremely important in metabolic processes, including smooth muscle cell relaxation, 
proliferation of platelet aggregation, neurotransmission, and immune regulation (Fang et al. 
2002). On the other hand, NO can also be harmful. During inflammation, macrophages and 
neutrophils release NO, which acts as a precursor for oxidants such as peroxynitrite, nitrogen 
dioxide, and the SOH, causing deleterious effects. 
Polyunsaturated fatty acids are highly susceptible to free radical attack (Rice-Evans 
1995). Their ensuing oxidation primarily results in lipid peroxidation, aradical-initiated 
chain reaction that is self-propagating in cellular membranes. An initiating free radical 
extracts a hydrogen atom from one of the polyunsaturated fatty acids, producing a lipid 
radical (Fang et al. 2002). Molecular oxygen then reacts with the lipid radical, yielding a 
lipid peroxy radical, which further propagates the peroxidation chain reaction by removing a 
hydrogen atom from an adjacent lipid to form lipid hydroperoxide (Fang et al. 2002). Chain 
propagation continues until scavenged by antioxidants or when terminated by the 
combination of two lipid peroxyl radicals to form less harmful products (Esterbauer 1995). 
The following reactions illustrate the steps involved in lipid peroxidation. 
Figure 2. (Esterbauer 1995) 
~~ 
LH + x` ~ L` + xH (Initiation} 
L` + O2 --~ LOO` {Lipid Peroxy Radical Formation) 
LOO` + LH —~ LOOH + L` (chain Propagation} 
LOO` + AOH --~ LOOH + AO` (Antioxidant Scavenging} 
LOO` +LOO' —~ non-radical product + 0 2 (Termination} 
Lipid peroxidatian is often an isolated event within cellular membranes, causing 
profound effects on membrane function. The lipid peroxy radicals formed during the 
modification of the polyunsaturated fatty acid side-chains of lipids amplify lipid 
peroxidation, oxidize cholesterol, react with proteins, and impair functions of enzyme and 
receptor systems {Rice-Evans 1995}. The consequences that result from the peroxidation of 
membrane lipids include loss of polyunsaturated fatty acids, decrease in lipid fluidity, 
alteration of membrane permeability, adverse effects on membrane-associated enz~rnes and 
receptors, altered ion transport, release of material from subcellular compartments, and 
generation of cytotoxic metabolites of lipid hydroperoxides (Rice-Evans 1395}. 
In addition to its deleterious effect within cellular membranes, lipid peroxidation 
products are carried by plasma lipoproteins, thus leading to the oxidation of lipoproteins, 
especially LDL {Kontush and Beisiegel 1999). Oxidation of LDL is a vital step in the 
pathogenesis of atherosclerosis, contributing to arterial wall inflation and promoting 
leul~ocyte adhesion to endothelial cells {Goudev et al. 2000). Oxidized LDL are t~~ken up by 
macrophages and enlarged to farm lipid-laden foam cells that become trapped in blood vessel 
walls. The result is a massive acc~~.mulation of foam cells, l~nown as atherosclerotic plaques 
or lesions, in the subendothelial space of arteries (Esterbauer 1995). Additionally, oxidized 
LDL contain cytotoxic lipid peroxidation products that may cause constant irritation to the 
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endothelial cell layer and provoke other detrimental effects, such as endothelial cell death, 
platelet aggregation, release of growth factors, accumulation of i~lflan~matory cells, and 
increased infiltration of LDL (Rice-Evans 1995). Progression of these events may eventually 
lead to cardiovascular events, such. as myocardial infarction or stroke. 
Proteins are prone to damage by oxidative stress by various mechanisms. Reactive 
oxygen species that attack amino acids on proteins may break peptide bonds in the backbone 
or disrupt the structure of the protein, eliciting changes in secondary or tertiary structures, 
leading to premature degradation. Denaturation of protein can impair enzymatic activity and 
modify membrane and cellular fiunctions, including intracellular transport and metabolism 
{Rice-Evans 1995). Another protein modification is the conversion of side chains of ~o 
acid residues, such as arginine and lysine, resulting in the formation of protein-bound 
carbonyl groups. These develop more rapidly than lipid peroxidation products and t~~.ke 
much longer to degrade. 
Pro-oxidants interfere with normal metabolism by oxidizing DNA, resulting in 
mutation. Reactive oxygen species, such as SOH, extract hydrogen from the purinic and 
pyrimidinic bases of nucleic acids {Boveris et al. 1999) and cause single and double strand 
damage (Bohr et al. 1995}. The *DH also reacts with DNA by adding double bonds of DNA 
bases (Cooke et al. 2003). Extensive oxidative DNA damage may result in cytotoxicity, 
mutagenicity, and gene rearrangements, which may alter cellular phenotype (Bohr et al. 
1995} and be responsible for genetic defects. Additionally, DNA mutation is a crucial step in 
careinogenesis and is likely to play an important role in the pathogenesis of other diseases as 
well {Cooke et al. 2003). 
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Iron Excess 
Iron is an essential nutritional element in life. It is a component of hemoglobin and 
myoglobin, as well as a component of enzymes that are necessary for normal cell function. 
Iran also catalyzes critical redox reactions needed for many physiological functions. For 
example, it is involved in energy production, and as part of ribonucleotide reductase, it is 
involved in DNA synthesis (Orino et al. 2001). Twa thirds of the body's iron is found in the 
oxygen-carrying protein, hemoglobin, with smaller amounts in myoglobin and various 
enzymes (Gutteridge 1995). The bound iron is transported in the body by transferrin, while 
excess iron is stored as ferritin and hemasiderin (Emerit et al. 2001; Gutteridge 1995). 
Ferritin has the capacity to sequester a vast quantity of iron and the ability to maintain it in a 
nontoxic form (Eme~t et a1.2001)and available for use, if needed. in healthy individuals, 
the excess iron pool is small but can be slightly elevated in people at risk far iron overload, 
such as in hemochromatasis and conditions of tissue damage. Excess iron accumulates in 
organs, such as the heart and blood vessels, and may catalyze pathologic reactions involving 
free radical generation, which in turn leads to cell death and organ dysfunction (Horwitz 
1999}. Iran has also been found to be elevated in a number of degenerative diseases of 
aging, such as Parkinson's disease, Alzheimer's disease, and CVD (Walter et al. 1999). 
It has recently been suggested that excess iron indirectly increases the risk of CVI~ by 
increasing oxidative stress (Salonen 1993; Horwitz and Rosenthal 1999). In vitro, free iron 
catalyzes the Haber-Weiss reaction, wherein the ~z-• anion and Hz~z react to generate a •QH 
(figure 3) (Emerit et al. 2001; Morris et al. 1995). Iran also participates in the Fenton 
reaction, reducing H~~z to a •OH {Walter et al. 1999). Such reactions cause oxidative 
damage and may enhance the risk for disease. Iron additionally catalyzes the chain 
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Figure 3. Haber-Weiss and Fenton Reactions 
Haber-Weiss reaction (Morris et al 1995) 
0 2"• + H2O2 —~ 0 2 + HO- + •OH 
Fenton reaction  (Emerit et al. 2001 } 
Fe3+ + 02• - --~ Fe2+ + 02
Fe2+ + H2O2 —~Fe3+ + HO- + •OH 
reaction of lipid peroxidation (van Jaarsveld and Pool 2002}, thus producing oxidized LDL 
(Naimark et al. 1996). Iron also elicits smooth muscle cell proliferation, which indirectly 
increases the susceptibility of LDL to oxidation by reducing antioxidants in plasma, thus 
promoting atherogenesis by affecting blood lipid concentaations (van Jaarsveld and Pool 
2002). Kiechl et al. (1997} addressed the connection between serum ferritin concentrations 
and the progression of carotid atherosclerosis in a random sample of 826 men and women 40 
to 79 years of age. They found strong evidence that iron promotes lipid peroxidation and 
thus may cause atherogenesis. High iron stores also down-regulate NO synthesis by the 
arterial wall, which in turn is associated with atherosclerosis. In a study of females aged 14 
to 19, NO concentrations increased gradually as iron deficiency progressed, but then 
signif candy decreased after hemoglobin concentrations were normalized by iron 
supplementation (Choi et al. 2002}. Iron-mediated processes are also capable of causing 
myocardial injury during reperfusion. Hydrogen peroxide and the 0 2-• radical are generated 
during ischemia and reperfusion and are usually weak oxidants. But, in the presence of iron, 
these radicals can cause production of •OH (Horwitz and Rosenthal 1999) and cause damage. 
On the contrary, other studies have found no association between ferritin and CVD, 
thus other factors most certainly contribute to the increased risk of myocardial infarction. 
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Williams et al. (2002} progressively evaluated CVD measures in individuals and found an 
association between serl~.m ferritin and both anthropometric and metabolic biochemical risk 
factors. Serz~.m ferritin was also strongly associated with CRP in women, thus suggesting that 
ferritin may be a surrogate measure of inflammation in women. However, this association 
could be due to infection, because ferritin concentrations rise in response to acute infection to 
protect against proliferation of microorganisms Williams et al. 2002). Therefore, it may be 
that infection and inflammation contributes to the pathogenesis of atherosclerosis. 
Preventive Approaches 
The human body provides many protective mechanisms against cellular injury and 
disease. Hormones and antioxidants both play a part of the body's defense system. 
However, diet and physical activity also play a role in reducing the risk of disease. 
Mormon e T'h espy 
Many women choose to take hormone therapy (HT) as a way of relieving menopausal 
symptoms. Hormone therapy may also have several potentially beneficial vascular effects, 
including reductions in LDL-C, increases in HDL-C, arterial dilation, and reductions in 
platelet aggregation (Nevin and Pharr 2002), as well as favorable increases in insulin 
sensitivity and antioxidant activities. Hence, if the protection of estrogen is lost when 
women become estrogen-deficient after menopause, it follows that ET or estrogen plus 
progesterone (EPT) would minimize susceptibility to CVD and other associated diseases 
(Sullivan 2003). 
Unopposed Estrogen Therapy 
In the mid 1990's, evidence indicated a major role for ET in the primary and 
secondary prevention of CVD (~~evin and Pharr 2002}. A nine-week administration of oral 
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estrogen in postmenopausal women showed that ET also improved flow-mediated 
endothelium-dependent vasodilatation (Lieberman et al. 1994). The postmenopausal 
estrogen/progestin intervention trial (PEPI 1995) investigated the effects of different 
hormone regimens and revealed that estrogen alone or estrogen with progestin improved 
lipoproteins and Lowered fibrinogen concentrations; however, the unopposed estrogen had 
more favorable effects on HDL-C status. The mechanism by which ET elicits 
cardioprotective effects is still unclear. Proposed mechanisms include changes in lipid 
metabolism, blood pressure, carbohydrate metabolism, coagulation factors, and endothelial 
function (PEPI 1995). 
Despite the beneficial findings above, recent randomized clinical trials have shown 
that estrogen therapy may not always be optimal for treating or preventing medical 
conditions associated with the aging process (Nevin and Pharr 2002). Disadvantages of ET 
include potential increases in the risk of breast cancer, vaginal bleeding, and endometrial 
cancer (Glazier and Bowman 2001). Estrogen has also been shown to raise TG 
concentrations as a result of an increase in VLDL production (LaRosa 1998). These risks, as 
well as the benefits, vary from individual to individual; therefore, it is not always clear that 
ET is the best option to combat menopausal symptoms and consequences. 
Estrogen plus Progesterone 
The EPT regimen is an additional pharmacological therapy option that effectively 
reduces the symptoms of menopause, although the primary role of progesterone is to protect 
the endometrium from hyperplasia and cancer. EPT has also been shown to reduce the 
concentration of cellular adhesion molecules (Goudev et al. 2000), as well as to produce 
favorable effects on circulating lipoproteins, particularly by lowering LDL-C concentrations 
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(LaRosa 1998). In addition, it may reduce the activity of osteoclasts and thus slow bone 
loss. 
In contrast, many studies have shown that EPT does not reduce the prevalence of 
atherosclerosis nor any other events associated with CVD (Sullivan 2003 ). In the Heart and 
Estrogen~P'rogestin Replacement Study (HERS), treatment with oral EPT did not reduce the 
rate of CAD events in postmenopausal women with established coronary disease. In 
addition, the EPT increased the rate of thromboembolic events and gallbladder disease 
{Hulley et al. 1998). Also, the medical conununity is very concerned about the effect of EPT 
on breast cancer risk. Schairer et al. (2000) found that an EPT increased breast cancer risk 
beyond that associated with estrogen alone during afifteen-year follow-up study in 
postmenopausal women. Also, recently, the EPT arm of the Women's Health Initiative was 
halted due to evidence of increased risk of invasive breast cancer, as well as increased risk of 
CAD, stroke, and pulmonary embolism in women (WHI 2002). Many prospective studies 
also suggest an early increase in cardiovascular events following the initiation of EPT. The 
HERS study reported that EPT appeared to increase the risk for primary CAD events in the 
first year of therapy, but this decreased in subsequent years (Hulley et al. 1998). In addition, 
EPT may result in a three-fold increase in venous thromboembolism, as well as risks for 
ovarian cancer and asthma {Nevin and Pharr 2002). Although minimal in comparison to the 
limitations noted above, EPT is also associated with adverse effects, such as uterine bleeding. 
Thus, the balance between the risks and benefits of EPT appear to be ever evolving and 
perhaps somewhat contradictory depending upon the study. Nonetheless, HT is not indicated 
or approved for reducing CVD risk in postmenopausal women. 
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say protein 
Many adults take a preventive approach by identifying risk factors and establishing 
lifestyle patterns that promote positive health and well being. Diet and physical activity play 
a major role in reducing the susceptibility to disease. Populations in Asian countries 
consume significant daily amounts of soy protein in products such as soymilk, tofu, and 
tempeh (Erdman 1995). Coincidently, the incidence of CVD is lower in these countries than 
in western nations (Glazier and Bowman 2001). Despite this fact, some Americans are still 
cautious of consuming soy protein. They believe that soy poses potential risks for enhanced 
breast tumor growth and abnormal sexual development, as well as adverse effects on the 
central nervous system. To assess hormone-related risks, Jenkins et al. (2000a) examined the 
consumption of soy protein foods in thirty-one hyperlipidemic men and postmenopausal 
women. They found no evidence of increased urinary estrogenic activity, a marker for 
hormone-dependent cancers, suggesting little or no increase in the risk for adverse health 
effects. Also, while allergic reactions to soy products may exist, they vary between 
individuals and are very rare in adults. Many Asian populations typically consume 20 g of 
soy protein daily {Erdman 1995} and have done so for hundreds of years, implying that soy 
protein consumption is safe. In addition, soy protein has been successfully used as a protein 
source in infant formulas. Safety, however, is not the only issue causing the low acceptance 
of soy protein in Western countries. The beany or bitter aftertaste of many soy foods 
prevents acceptance by many individuals and does not bring about the same positive 
response as "meat," "eggs," or "milk" (Erdman 1995). In order to encourage and increase 
the addition of soy foods into the western diet, the public will need to be educated about the 
benefits of soy protein. 
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The potential benefits associated with soy consumption include a decreased risk of 
several cancers, including breast, prostate, and colon, as well as CVD and osteoporosis, 
Scheiber et al. (2001) investigated the effect of soy protein on markers of both CVD and 
osteoporosis in normal postmenopausal women and revealed that the consumption of soy 
foods, containing approximately 60 mg of isoflavones, for 12 weeks resulted in signif cant 
reductions in risk factors of both CVD and osteoporosis. Subjects had significantly higher 
serum HDL-C concentrations, as well as increased lag-time for LDL peroxidation after 
intervention. Plasma total homocysteine concentrations have also decreased with the 
addition of 30-50 g of soy protein per day to alipid-lowering diet (Tonstad et al. 2002). In 
addition, ameta-analysis by Anderson et al. (1995) concluded that soy protein, in substitution 
for animal protein, produces significant decreases in serum concentrations of TC, LDL-C, 
and TG. However, this decrease in cholesterol via cons~ption of say protein varied 
according to initial cholesterol concentrations. This greater lipid-lowering effect of soy seen 
in hypercholesterolemic subjects, compared to that in normolipidemic subjects, hay also been 
documented in other studies (Vigna et al. 2000; Tonstad et al. 2002). 
Other possible benefits of soy protein with isoflavones include relief of menopausal 
symptoms. Japanese women generally have delayed menopause and reduced symptoms, 
perhaps due to their high consumption of soy products (Sirtori 2001). However, some 
studies have found little or no effect in the number of hot flushes in postmenopausal women 
consuming a soy protein enriched diet (Vigna et al. 2000; St. Germain et al. 2001). Thus, the 
interindividual variability in response makes results unpredictable. 
Many mechanisms have been proposed as being responsible for the 
hypocholesterolemic effect of soy protein. A popular hypothesis is that it mimics the effect 
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of statin drugs (3 -hydroxy-3 -methylglutaryl coenzyme A reductase inhibitors [HMS-~oA 
reductase] } and up-regulates LDL receptors. Low-density lipoprotein receptors are 
chronically depressed in hypercholesterolemia, and soy protein may exert an up-regulation of 
LDL receptors, thus lowering LDL-~. The 7S globulin, one of the major storage proteins of 
soybeans, may be responsible for this direct up-regulation of LDL receptors. Lovati et a1. 
(1992} found that this soybean globulin could effectively induce LDL receptors in a human 
liver cell line derived from normolipidemic subjects. However, this up-regulation may also 
be due to alterations in hormone concentrations. Soy consumption in animals has been 
shown to increase thyroxin and thyroid stimulating hormone (Forsythe 1990), thus increasing 
LDL receptor activity, HMS-CoA reductase activity, and bile acid excretion (Patter 1995}. 
Additionally, a high insulin-to-glucagon ratio that is associated with an increased risk of 
~vD decreases after feeding soy protein (Ham et al. 1993). Another passible mechanism 
may be that soy protein alters bile acid excretion by increasing fecal excretion of bile acids, 
thus causing the removal of cholesterol from the bloodstream to be used for enhanced bile 
acid synthesis (Potter 1995). Although this mechanism would result in a reduced 
concentration of blood cholesterol, it has only been consistently documented. in animals 
(Huff and Carrot 1980). 
Interest has also centered on finding the component of soy that is most responsible for 
its cholesterol-lowering ability. Soy components identified as being likely to have protective 
effects include saponins, sphingolipids, phenolic acids, phytate, and trypsin inhibitors. Also, 
soy has a low lysine-to-arginine ratio. Arginine is less hypercholesterolemic than lysine and 
thus may be responsible for the reduction in serum cholesterol. Although all of these 
components have been researched, most attention has focused on soy isoflavones. Studies 
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have also shown that phytate has some beneficial effect on disease prevention (Shamsuddin 
1995; Jariwalla et al. 1990}; however, it has received less attention compared to the other soy 
components. 
Soy Isoflavones 
Phytoestrogens are plant estrogens that occur naturally in plants, fruits, and 
vegetables. They are very similar to selective estrogen receptor modulators and thus have 
the potential to deliver the beneficial effects of HT without the undesired health risks 
{Scheiber et al. 2001). The three main types of phytoestrogens are coumestans, lignans, and 
Isoflavones, the Latter of which are the most potent and most investigated {Glazier and 
Bowman 2001) and are found primarily in soybeans. There are three major varieties of 
Isoflavones {genistein, daidzein, and glycitein), but genistein and daidzein are the two most 
commonly studied. Isoflavones have been researched mainly because of their relationship 
with CVD, cancer, osteoporosis, and menopausal symptoms. Reported actions include 
cholesterol-lowering, thyroxin, and antioxidant activities, as well as enhanced arterial 
compliance (Nicolosi et al. 2001). Isoflavones also possess weak estrogenic activity {Jenkins 
et a1. 2002} and are structurally similar to human estrogen in that they possess a phenolic ring 
that enables them bind to estrogen-a and estrogen-(3 receptors in humans (Glazier and 
Bov~~nan 2001). However, Isoflavones compete with estradiol far these binding sites, thus 
acting as estrogen antagonists in some tissues. 
The effect Of say protein on reducing hypercholesterolemia is mostly attributed to the 
presence of Isoflavones. Goodman-Grruen and Fritz-Silverstein (2001) investigated usual 
isoflavone intake from diet in postmenopausal women and found that it was inversely related 
to obesity, fasting, and post challenge insulin, as well as positively associated with HDL-C 
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concentrations. The Framingham Offspring Study also associated phytoestrogen (isoflavones 
and lignans) intake with a favorable cardiovascular risk profile (de I~leijn et al. 2002). 
However, some studies have found no effect of isoflavones on blood lipids. A 55-mg 
isaflavone supplement given to men and postmenopausal women for 8 weeps elicited no 
improvement in serum lipid concentrations (Hodgson et al. 1998). Additionally, Hsu et al. 
(2001) found that supplementing 150 mg of isoflavones per day for 6 months to normal 
postmenopausal women educed no significant change in plasma lipids. Therefore, the effect 
of isoflavones on serum lipids in humans remains unclear, and these discrepancies may be 
attributed in part to interindividual variability or initial cholesterol concentrations. Also, 
adding 10 mg and 73 mg isoflavane-rich soy protein to a low-fat diet far 3 months in 
hyperiipidemic men and postmenopausal women both reduced blood lipids, homocysteine 
concentrations, and blood pressure (Jenkins et al. 2002), suggesting that isoflavones may not 
be the protective component in soy. 
In addition to altering blood lipids, isoflavones may also affect CVD by improving 
arterial compliance, vascular function (Sirtori 2001), and antioxidant status, the Later of 
which may be due the ability of isoflavones to quench free radicals in vitro, thus donating 
hydrogen atoms to free radicals and making them less reactive (Mitchell et al. 1998). Many 
studies show that genistein and daidzein protect against oxidation of LDL. Jenkins et al. 
(2000b} found that the consumption of say breakfast cereals in 25 hyperlipidemic men and 
postmenopausal women reduced oxidized LDL. Also, following a 12-week intervention with 
soy foods high in isoflavones, Scheiber et al. (2001) found that ser~nn daidzein, genistein, 
and total isoflavone concentrations were positively correlated with LDL oxidation lag time in 
postmenopausal women. In addition, the consumption of readily available soy foods has 
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been also associated with reduced circulating oxidized LDL (Jenkins et al. 2000a). Based on 
these effects on LDL oxidation, one may postulate that consuming soy protein, specifically 
isoflavones, may reduce the progression of atherosclerosis. 
Phytic Acid 
Phytate (inositol hexaphosphate, IP6) is a naturally occurring compound found in 
legumes, cereals, whole grains, seeds, and nuts. As a constituent of fibrous products, phytate 
is thought to contribute to the prevention of cancer and other chronic diseases. It is also 
found in human cells as IP6 and its metabolites, where it is important far many cellular 
processes. Less phosphorylated forms of phytate possess similar characteristics as IP6, such 
as its ion-chelating ability (Miyamoto et al. 2000), and are responsible for many of phytate's 
cellular functions. Unfortunately, the absorption, metabolism, tissue distribution, and 
excretion of phytate in humans is not clear. Recently, Grases et a1. (2001) found that the 
level of plasma and urinary IP6 depended on dietary phytate intake, suggesting that a small 
amount of absorption may occur in humans. Conversly, in rats, when administered with 
drinking water, IP6 is rapidly absorbed through the stomach and upper small intestine 
(Sakamota et al. 1993). 
A considerable amount of attention is being paid to the anticancer and anti-CVI? 
activities of phytate. There are many proposed actions, but most important is phytate's 
ability to bind to metals. Its unique structure of phosphate groups gives it tremendous 
potential to chelate calcium, iron, and zinc ions (Jariwalla et al. 1990). Because of this 
activity, the consumption of phytate may be a health risk to those suffering from mineral 
deficiencies. However, in the case of healthy postmenopausal women, this characteristic 
may function as an antioxidant property, protecting against oxidative damage. Phytate's iron 
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chelating quality hinders iron's ability to participate in the Fention reaction and catalyze •OH 
formation (Hawkins et al. 1993}, thus decreasing cellular injury as is seen in chronic disease 
and cancer. Phytate may decrease atherosclerotic lesion formation by preventing the 
absorption of iron, thus preventing lipid peroxidation {Ko and Godin 1991; Shamsuddin 
1995) and oxidative damage to circulating proteins (Potter 1995). Supporting this theory, 
Porres et al. (1999) found that phytate in corn and soy was protective against lipid 
peroxidation in the colon of pigs with moderately high levels of dietary iron. 
Phytate may also protect against CVD due to its ability to reduce blood lipids. 
Jariwalla et al. (1990) found that adding phytate to acholesterol-enriched diet for six weeks 
significantly lowered serum TC and TG in rats; however, the mechanisms by which these 
occur are still unknown. Binding to zinc may offer alipid-lowering mechanism by lowering 
the zinc-to-copper ratio, which is associated with high plasma cholesterol concentrations 
(Potter 1995; Jariwalla et al. 1990; Klevay 1977). In addition to these mechanisms, phytate 
may also effectively inhibit platelet aggregation, thus contributing to the prevention of 
thromboembolic events and CVD (Vucenik et al. 1999}. Therefore, phytate shows promise 
as a therapeutic or preventive dietary approach to reducing chronic diseases. 
The question still remains whether isoflavones, phytate, or other soy components, are 
needed to achieve optimal health benefits. The effect of isoflavones and phytate may simply 
be additive, synergistic, or complimentary to soy protein and/or other constituents (Sirtori 
2001). To promote cardiovascular health, it may be more beneficial to consume soy 
products containing all the components rather than taking individual components. 
Consuming a diet low in saturated fat and cholesterol may also help to achieve optimal health 
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status ~Sirtori 2001). The effects of aging are inevitable, but with current scientific progress, 
it may be possible to delay the aging process or at least make it more tolerable. 
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SOY ISOFLAVONES AND PHYTIC ACID: EFFECTS ON BLOOD 
LIPIDS AND OXIDATIVE STRESS IN POSTMENOPAUSAL WOMEN 
A paper to be submitted to the American Journal of Clinical Nutrition. 
Heather M. Barwick, Laura N. Clark, D. Lee Alekel, and Manju B. Reddy 
ABSTRACT 
Background: Postmenopausal women are at risk for developing cardiovascular disease 
(CVD} due to unfavorable blood lipid profiles and increased oxidative stress. Soy protein 
consumption may help protect against these risk factors. 
Objective: To determine the effect of the soy protein components, isoflavones and phytate, 
on the risk of CVD in postmenopausal women. 
Design: In a double-blind study, 55 postmenopausal women were randomly assigned to 1 of 
4 soy protein isolate (SPI) treatments: low phytate, low isoflavone (LP/LI); normal phytate, 
low isoflavone (NP/LI); low phytate, normal isoflavone (LP/NI); or normal phytate, normal 
isoflavone (NPiNI). Subjects consumed 40 g soy protein/d for 6 wk. Blood Lipids (total 
cholesterol [TC], low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein 
cholesterol [HDL-C], triacylglycerol [TG]) and oxidative stress indices (protein carbonyls 
[PC], oxidized low-density lipoproteins [oxLDL], 8-iso-prostglandin-F2a [PGF2a]) were 
measured at baseline and 6 wk. 
Results: Although the normal-isoflavone treatments showed a marginal effect on oxLDL, 
there was no overall significant effect on oxidative stress indicators. Both treatment groups 
~~ 
consuming normal isoflavone levels showed a significant decrease in TC (p<0.05) &LDL-C 
(p<0.0 I }after six weeks; however, the contrast between the low-isoflavone and normal-
isoflavane groups was not significant (TC p~0.16, LDL-C p=0.1 ~). The normal-phytate 
versus low-phytate treatments showed a trend toward decreasing PC and PGF2a; however, the 
differences were not significant. 
Conclusions: Isoflavones, regardless of phytate content, may moderately reduce risk of 
CVD by favorably altering blood lipids. Phytate, regardless of isoflavane content, did not 
show a significant effect on either blood lipids or oxidative stress indicators. 
I~:E~ 't~()RDS Postmenopausal women, oxidative stress, Cardiovascular Disease, Soy 
Protein, Isoflavones, Phytate, Blood Lipids 
INTR(3D~TCTIf 3N 
1VIen are usually at higher risk of developing cardiovascular disease (CVD) than 
women. After menopause, the risk for women becomes similar to that of men. The lack of 
estrogen may be responsible for affecting antioxidant systems, as well as lipid and 
lipoprotein concentrations (Goudev et al. 2000), both of which are implicated in the 
pathogenesis of CVD (Saito et al. 2003; Cooke et al. 2003). 
Soy protein consumption has been shown to significantly decrease serum 
concentrations of TC, LDL-C, and TG (Vigna et al. 2000; Scheiber et al. 2001 }. This 
cholesterol-lowering activity is generally attributed to the Isoflavones in soy. Adding soy 
protein with Isoflavones to a low-fat diet for 3 months in hyperlipidemic men and 
postmenopausal women significantly (p<0.01 }reduced TC and LDL-C (Jenkins et al. 2002}. 
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Conversely, other studies with isoflavone-rich soy protein showed no effect on serum lipid 
concentrations {Dent et al. 2001). A 55-mg dose of isoflavones in men and postmenopausal 
women for 8 weeks showed no improvement in serum Lipid concentrations (Hodgson et ai. 
1998). Additionally, Hsu et al. (2001) found that 150 mg of isoflavones per day for 6 months 
to normal postmenopausal women elicited no significant change in plasma lipids. These 
conflicting results may be due to subject selection, large interindividual variation, or various 
doses of isoflavones. Hence, the effect of isoflavones on serum lipids in humans remains 
unclear. 
Soy isoflavones may also possess antioxidant properties, protecting against oxidation 
of LDL (Jenkins et al. 2000). Following a 12-week intervention with soy foods high in 
isoflavones, serum daidzein, genistein, and total isoflavone concentrations were positively 
correlated with LDL oxidation lag time in postmenopausal women (Scheiber et al. 2001). 
One theory is that isoflavones quench free radicals by donating a hydrogen atom to free 
radicals, thus making them Less reactive (Mitchell et a1. 1998). However, this has only been 
demonstrated in vitro. Another possible mechanism of isoflavones may be by increasing 
antioxidant concentrations. A 30-d administration of genistein (50 ppm) has been shown to 
increase antioxidant enzymes in mice (Cai and Wei 1996), and a 3 -wk, 44-mg dose of 
genisteinld (40 g protein) raised the total antioxidant status in men (Rossi et al. 2000}. 
Phytate, another component of soy protein, was originally considered an anti-nutrient, 
but may be beneficial in some circumstances. Phyltate has a stronger free radical quenching 
ability than isoflavones, and can bind minerals, such as iron, zinc, and calcium. Because of 
this phytate makes iron unavailable to participate in the Fention reaction and catalyze 
hydroxyl radical formation in vitro (Rao et al., 1991). Thus, phytate may prevent oxidative 
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damage, such as lipid peroxidation (Ko and CJodin 1991; Porres et al. 1999) and 
atherosclerotic lesion formation {Potter 1995}. Although phytate is known to be absorbed in 
rats {Sakamoto et al. 1993), a very small absorption was found in humans {Orases et al. 
2001 }. Based on its antioxidant properties, even a small amount may protect against 
oxidative stress (Rao et al. 1991 }. 
In addition, to its antioxidant activities, phytate has shown lipid-lowering activities. 
Jariwalla et aI. (I 990) found that adding phytate to acholesterol-enriched diet for six weeks 
significantly lowered serum TC and TG in rats. However, data in humans are limited. 
Binding to zinc, and thus Lowering the zinc-to-copper ratio, which is associated with high 
plasma cholesterol concentrations, may be responsible for the lipid-lowering effects {Potter 
1995; Jariwalla et al. 1990; Klevay et al. 1977). The overall hypothesis of this study is that 
soy protein will reduce the risk of CVD, specifically that isoflavones will favorably alter 
blood lipid concentrations and that phytate will decrease oxidative stress indices. 
SUBJECTS AND 1ViETHC1DS 
Study Design 
In this 6-week, double-blind study, 5 5 free-living postmenopausal women were 
randomly assigned to 1 of 4 soy protein isolate (SPI} treatments provided by the Solae 
Company {St. Louis, MO): low phytate and low isoflavone content {LP/LI, n=1A~); normal 
phytate and low isoflavones (NP/LI, n=13); low phytate and normal isoflavox~es (LP~l~TI, 
n=14}; or normal phytate and normal isoflavones {NP/I~TI, n=14). All subjects were 
Caucasian, with the exception of one Asian woman. The women were supplied with two 20 
g packetsld of protein {84 total packets) in a powder form.. They were also given recipes to 
incorporate the powder into fruit smoothies or other foodstuffs. Two weeks prior to and 
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during the intervention, subjects were required to avoid all supplements, including vitamins, 
minerals, and herbal remedies. Subjects were also required to avoid phytate {Harland and 
Oberleas 1987; Reddy 2002) and isoflavone-rich (Stevens and Associates, Inc. 2001) foods 
during the intervention. 
The phytate and aglycone contents, respectively, of each treatment per 40 g soy 
protein powder were as follows: LPILI=0.22 g, 1.2 mg; NP/LI=0.b4 g, 1.2 mg; LP/~tiTI=0.22g, 
85.8 mg; NP/NI=0.78 g, 84.E mg. Alcohol extraction was used to prepare the low-isoflavone 
SPI, and phytase hydrolysis was used to prepare the low-phytate SPI. 
Subject Selection 
Postmenopausal women were recruited throughout central Iowa from Apri12002 
through November 2002. Approximately 3 00 women responded, and telephone interviews 
were conducted to screen the potential participants to ensure they met the inclusion and 
exclusion criteria. Subjects were included in the study if they were postmenopausal (last 
menses > 12 months prior to intervention), healthy {no chronic disease or medication use), 
and had a body mass index (BMI) 19-34 kg/m2. Women were excluded if they had a chronic 
disease, had a hysterectomy, had t~~.ken hormone therapy <12 months prior to intervention, 
andlor had used cigarettes or hormone creams <6 months prior to intervention. Based on 
these criteria, 5 7 women were qualified to participate. However, two of the women 
withdrew due to intolerable gastrointestinal side effects. The remaining 5 5 women 
completed the 6-week .intervention with little or no gastrointestinal side effects. 
Data Collection 
Health and medical history, nutrition history, and soy food intake (Dirk et al 1999) 
were obtained at baseline using interviewer-administered questionnaires. Usual dietary 
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intake was also assessed at baseline with a food frequency questionnaire from Block Dietary 
Data Systems (Berkeley, CA). Overnight fasted blood samples were collected at baseline 
and week-6 and were frozen at -80°C until used. A standard reference laboratory (Quest 
Diagnostics, St. Louis, MO) analyzed serum and plasma for blood lipid profile (total 
cholesterol [TC], low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein 
cholesterol [HDL-C], triacylglycerol [TG]) and other blood chemistry analytes. Oxidative 
stress indices (protein carbonyls [PC], oxidized low-density lipoproteins [oxLDL], and 8-iso- 
prostglandin-F2a [PGF2a]) were measured in the laboratory at Iowa State University. Protein 
carbonyls were measured using a slight modification of the procedure described in Reznick 
et al. (1992). Briefly, plasma was mixed with dinitrophenylhydrazine dissolved in 
hydrochloric acid (HCl), accompanied by blanks in HCl alone. Protein was then precipitated 
with 20% (w/v) trichloroacetic acid (TCA) and washed once with 10% TCA and three times 
with 5 ml of a 1:1 ethanollethyl acetate mixture. Finally, precipitates were dissolved in a 6 
M guanidine-HCl solution. Absorbance was measured spectrophotomically at 380 nm. 
Plasma oxidized low-density lipoprotein was determined using an enzyme-linked 
immunoassay (ELIZA) kit from ALPCO Diagnostics (Windham, NH), and serum PGF2a 
(free and esterified) concentration was determined using a direct ELIZA kit from Stressgen 
Biotechnologies (Victoria, BC Canada.). 
Statistical Analysis 
Statistical analysis was performed with SAS (Version 8.0). Student t-test was used to 
determine the mean difference between baseline and week-6 for each treatment. The 
differences in percent change ([baseline concentrations -week-6 concentrations I baseline 
concentrations] * 100) among the treatments were analyzed using analysis of variance 
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(ANfJVA) with Duncan's multiple range test. Contrast coding (LP vs NP and LI vs NI) was 
used to determine the individual effect of phytate and isoflavones. Pearson correlation 
analysis was used to determine the relationships among the risk factors. Statistical 
significance was set at p~0.05. 
RESI.TLT~ 
Compliance 
Compliance was based on the number of packets returned at the week-6 vislt. Most 
of the women consumed 100% of their packets. However, four subjects returned, 2, 3, 4, and 
8 packets and two subjects requested 3 and 4 extra packets. These subjects were evenly 
distributed across the treatment groups. 
Subject Characteristics 
The age of subjects ranged from 47-72 years. The range of time since menopause 
was 1-20 years with a mean of ~.4 years. Thirteen subjects had smoked in earlier years, six 
subjects had experienced cancer (skin [n-4], breast [n-=1 ], cervical [nom 1 ]) but were all in 
remission, and one woman had two previous strokes that were not related to CVD. There 
were no other reported cardiovascular events or diagnosis of CVD. 
Twenty-eight and twenty-six of the subjects conveyed their health as good and 
excellent, respectively, whereas one reported her health as fair. Education levels were high 
school (sixteen), college (twenty-nine), and post-college (ten). Thirteen of the participants 
stated they had experienced iron deficiency at least once in their lifetime due to malnutrition, 
pregnancy, menstruation, or the onset of menopause. Thirty-six subjects (eight to ten per 
treatment) reported regular use of a multivit<~nin, and two subjects (LP/LI= 1, LF/J`~I-1) 
reported regular use of axi iron supplement. Thirty-five subjects (seven to eleven per 
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treatment) reported they were consuming soy or soy products prior to the intervention, 
although most conveyed it was irregular. 
Subjects' descriptive and daily nutrient intakes are reported in Table 1. None of the 
descriptive characteristics at baseline were significantly different among the treatment 
groups. The dietary intakes of macronutrients were within normal ranges and did not 
significantly differ among the treatment groups. Overall, intake of selected antioxidants 
{vitamins A, C, and E) was within the recommended allowance in each treatment group. 
Although vitamin C values were higher in two treatments (NP/LI, LP/NI), the difference was 
not significant. 
Oxidative Stress Indices 
Oxidative stress indices before and after intervention are presented in Table 2. The 
protein carbonyl concentrations were very low {0.2 nmoUmg protein), and there was no 
significant change from baseline in any treatment. At baseline, the PGF2a concentration in 
the NP/LI treatment group was significantly different {p=0.05) from that in the LP/LI 
treatment group, but not from the other two groups. For each of the treatments, the PGF2a
concentration decreased (Figure 1), but this was not significant. Although, the change in 
PGF2a concentration in the NP/LI treatment group was 14-29% higher than in the other three 
groups, it was not significant. The degree of reduction in PGF2a seemed to be related to the 
initial concentration, since the maximum decline was seen in the group that had the highest 
mean value at baseline. The mean oxLDL concentration ranged from 66-5 l U/L in each 
treatment. Similar to PGF2a, there was a reduction in each treatments group. The 10 U/L 
modest reduction in the LP/NI group (p=0.052) was greater than the 4-6 U/L reduction in the 
other groups (Figure 1). However, the differences were not significant based on ANOVA. 
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Overall, oxLDL concentrations decreased to a greater extent in the treatments containing 
normal isoflavone levels (7-10%} compared to the treatments containing low isoflavone 
levels (3-7%). Although PC decreased in each treatment except LP/NI, neither the 
reductions from baseline nor the differences among the treatments was significant. In 
general, the normal-phytate groups reduced PC 6-7% (Figure 1 }. 
To determine the effect of isoflavones and phytate individually, contrast coding was 
used to test which contrast (LP vs. NP; LI vs. NI) had a significant effect on each risk factor. 
The normal-phyltate containing treatments reduced PC 14 pmol/mg compared to 3 pmol/mg 
in the low-phytate containing treatments; however, this contrast was not significant (p=0.18} 
(Figure 3). Similarly, PGF2a decreased 265 pg/mL in the normal-phytate treatments 
compared to the 163 pg/mL decrease in the low-phytate treatments, but this contrast was not 
significant (p=0.6$). In contrast, oxLDL was reduced to a greater extent in the normal- 
isoflavone containing treatments (7.9 U/L) than in the low-isoflavone containing treatments 
(4.3 U/L), although this difference was also not significant (p=0.4}. 
Blood I.,ipid Concentrations 
Blood lipid values at baseline and week-6 are presented in Table 2. Baseline TC 
ranged from 222-23 5 mg/dL among all treatments. Total cholesterol concentrations declined 
after six weeks in all treatments; however, the normal-isoflavone groups had a greater 
reduction (14-16 mg/dL) than the low-isoflavone groups (Figure 2). In the LP/NI and NP/NI 
treatment groups, respectively, TC significantly declined (p=0.04 and p=0.01) from baseline. 
Similarly, LDL-C decreased with treatment in all groups (Figure 2), but the only significant 
reductions were noted in LPINI (p= 0.006) and NP/NI (p=0.002). The initial TG 
concentration in NP/LI was significantly higher than the other treatment groups. However, 
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there was no significant change from baseline in any treatment group. Similar to TG, there 
were no significant changes is HDL-C concentration in any treatment group, although there 
was a significant difference at baseline between NP/LI and NP/NI. 
Contrast coding revealed that the normal-isoflavone groups had a decline in TC by 
14.8 mg/dL, whereas the decline in TC in the low-isoflavone groups was 5.9 mg/dL (Figure 
4). Similarly, LDL-C decreased to a greater extent in the normal-isoflavone groups (15.0 
mg/dL) than in the low-isoflavone groups (6.4 mg/dL). However, neither of these 
differences was significant. Contrast coding illustrated that phytate had no effect on blood 
lipid concentrations. 
Correlation of CVD Risk Factors 
Correlations among baseline BMI, oxidative stress indices, and blood lipid measures 
are shown in Table 4. The highest positive correlations {p<0.0001 }were observed between 
TG and PGF2a, as well as among TC, oxLDL, and LDL-C. In addition, BMI highly 
correlated with TG (p<0.001), PGF2a (p<0.05), and oxLDL {p<0.05). High-density 
lipoprotein cholesterol negatively correlated with TG (p<0.0001) and BMI (p<0.0001), as 
well as with PGF2a {p<0,001) and oxLDL (p<0.05). 
DISCUSSION 
The soy health claim from FDA recommends a daily intake of 25 g soy protein {Stein 
2000), based on the amount needed to favorably alter blood lipid profiles. In this study, we 
chose to use 40 g/d soy protein in order to determine whether a higher intake would elicit 
beneficial effects on blood lipid profiles, as well as on oxidative stress indices in 
postmenopausal women, who are at high risk for CVD. This amount was also chosen based 
on previous human studies that investigated health benefits of soy protein (Dent et al. 2001; 
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Teede et al, 2001; Potter et al. 1998; Swain et a1.2002). In addition, to obtain the amount 
needed to show beneficial effec#s of dietary phytate, the subjects needed to consume such an 
amount of soy protein. Although, the amount of phytate provided daily from soy protein 
{O.f 4-0.78 g) was still lower #han the amount used in previous rat studies (9% w/w) that 
showed beneficial effects {Jariwalla et al. 1990). 
Subjects were recruited throughout the summer and fall seasons, which potentially 
might have affected exercise habits and/or dietary intake patterns during the intervention. 
However, #here was no change in BMI with intervention in each treatment, suggesting that 
the seasonal variation in either diet<a`y intake or physical activity had no effect. In addition, 
all the subjects consumed the same amount of protein, thus we did not expect any difference 
in the dietary intakes among the treatments. 
The NP/LI group had higher oxidative stress in terms of PGF2a, oxLDL, (Table 2) 
HDL-C, and TG (Table 3) concentrations. Although, the change in PGF2a was more evident 
in the NP/LI group, the percent change was lower than that in the LP/LI and NP/NI groups 
(Figure 1 }. In contrast to other published studies, the reduction in oxLDL with isoflavones 
was modest in our study. Exner et al. {2001) found that genistein effectively prevented 
glucose-mediated LDL oxidation in vivo. In addition, serl~.m daidzein, genistein, and total 
isofiavone concentra#ions positively correlated with LDL oxidation lag time in 
postmenopausal women following a 12-week intervention with soy foods high in isoflavones 
{Scheiber et al. 2001 j. It may be possible that the sample size in our study may have been 
too small to detect a significant change in oxLDL. The effect of isoflavones on reducing 
oxLDL may also depend on the oxidative status of the subjects at baseline, Although ~ 3 g/d 
soy protein for one month significantly decreased oxLDL in hyperlipidemic subjects (Jenkins 
~l 
et al. 2000}, it is not clear whether this effect can be found in normolipidemic subjects. In 
our study, there was a correlation between blood lipids and oxLDL, but the blood lipid 
concentrations were not high enough in our subjects to clarify them. as hyperlipidemic. 
Similar to the effects on oxLDL, but to a smaller extent, all of the treatment groups 
experienced a decline in PGFza concentrations, suggesting a soy protein effect. Phytate 
contrast notably decreased PGF2a by almost two-fold; however, neither of the contrasts had a 
signif cant effect (Figure 3). Although it was modest, the normal-phytate groups had a 
greater effect on PC than the normal-isoflavone groups. However, this may have been due to 
the overall increase in the LP/NI treatment group (Figure 1 }, thus comparing the low-phytate 
and normal-phytate treatments caused. a larger difference in the means. Phytate has a strong 
chelating ability for iron under in vitro conditions {Rao et a1. 19~ 1); however, it is possible 
that in vivo it does not reduce the free radical formation. It is also possible that the amount 
of phytate in the soy protein was not enough to see an effect, since absorption is low in 
humans {~ra~es et al, 2001). 
The modest effect of the normal- versus low-isoflavone treatments on reducing TC 
and LDL-C may have been due, in part, to the mean initial concentrations in TC {227-23 5 
mg/dL} and LDL-C (1 ~44+ 151 mg/dL}, although these values may not be considered to be that 
high. It has been demonstrated that soy isoflavones exert more pronounced affects in 
hypercholesterolemie than narn~olipidemic subjects (Vigna et al. 2000}. Additionally, 
consuming isoflavone soy-food diets for 1 month reduced blood lipids, homocysteine 
concentrations, and blood pressure in hyperlipidemic men and postmenopausal women 
(Jens et al. 2002), whereas Hsu et al. {2001 }found that supplementing 150 mg of 
isoflavones per day for 6 months to normal postmenopausal women educed no significant 
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change in plasma lipids. Dent et al. (2001) also found that isoflavone-rich soy protein for 24 
wk had no effect on circulating lipids in normal perimenopausal women. 
Although the differences were not significant, the increases in HDL-C for LP/LI and 
LP/NI were 2.1 and 7%, respectively (Figure 2). However, the low-isoflavone treatments, 
combined, produced an increase that was modestly different from the reduction caused by the 
normal isoflavone groups (Figure 4). In contrast, Goodman-Gruen et al. (2001) found that 
isoflavone intake in postmenopausal women was positively associated with HDL-C 
concentrations. The mean baseline TG concentration in the NP/LI treatment group was 
significantly and inexplicable higher (168 mg/dL) than in the other groups (100-112 mg/dL) 
(Table 3). However, the change from baseline was not significantly different among the 
treatments. Tonstad et al. (2002) saw a similar increase in TG concentrations following a 24- 
wk, 30-g and 50-g soy protein/d diet in men and women. In contrast to the modest effect of 
isoflavones, phytate had no effect on blood lipid concentrations. These results again do not 
support the rat studies that have shown lipid lowering effects of phytate. However, Jariwalla 
et al. (1990) used 9% (w/w) phytate, which was a higher amount than was given to our 
subjects, and they added the phytate to acholesterol-enriched diet, which may have affected 
the results. Also, rats absorb phytate more readily than humans (Sakamoto et al. 1993; 
Grases et al. 2001). 
The positive correlation of BMI with oxidative stress markers, oxLDL and PGF2a 
(Table 4) is noteworthy. Vasankari et al. (2001) found a similar correlation between BMI 
and oxLDL, whereas Suzuki et al. (2003) found no correlation between the two markers. 
Baseline BMI was also negatively correlated with HDL-C (Table 4), similar to what has been 
reported in other studies (Bautista.-Castano et al. 2003). Additionally, a negative correlation 
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between HDL-C and fat mass has also been reported {Ito et al. 2003 ), suggesting unfavorable 
HDL-C concentrations in overweight or obese individuals. Lowering BMI may be beneficial 
to reduce oxidative stress and I~DL-C. 
In conclusion, our study showed that the treatments containing normal isoflavone 
levels only had a modest change on oxidative stress markers and blood lipids. Also, 
isoflavones may have a greater effect on favorable altering circulating lipids and lipoproteins 
than phytate. In contrast, most of the oxidative stress indices were reduced more evidently 
with the phytate treatments. Compared to studies that only looked at total antioxidant status 
{Swain et al. 2002; Rossi et al. 2000), this study included many oxidative stress indicators to 
assess damage to proteins and lipids, which may be more indicative of oxidative damage. 
Based on the modest effects noted in this study, future studies with a larger number of 
subjects may be needed to produce more significant effects from isoflavones and phytate. 
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TABLE 1 
Baseline characteristics of subjects (mean [min-max]) 
Treatment 
LP/LI NP/LI LP/NI NP/NI 
(n=14) (n=13) (n=14) (n=14) 
Age (y) 56 59 58 60 
[49-70] [53-69] [47-72] [50-70] 
Weight (kg) 71 72.7 72.7 69.2 
[58.2-93.6] [59.0-96.8] [55.2-92.5] [52.3-92.4] 
Height (m) 1.7 1.6 1.7 1.7 
[1.5-1.8] [1.5-1.7] [1.6-1.7) [1.6-1.7] 
BMI (kg/m2) 25.9 27.9 26.5 25.3 
[18.6-32.9] [21.2-33.9] [19.9-32.0] [21.3-33.6] 
Dietary Intake/d* 
Energy (kcal) 1702 1766 1769 1647 
[515-2559] [763-2708] [877-2827] [1144-2595] 
Protein (g) 65 68 71 63 
[22-104] [30-108] [31-122] [39-103] 
Carbohydrate (g) 217 239 213 204 
[53-412] 119-405] [85-339] [146-328] 
Fat (g) 66 64 75 67 
[25-96] [22-113] [36-139] [30-105] 
Saturated Fat (g) 21 18 21 18 
[7-37] [6-30] [12-38] [9-26] 
Vitamin C (mg) 103 155 130 116 
[42-192] [99-312] [43-211] [50-170] 
Vitamin E (a-TE) 9 11 11 10 
[3-15] [5-19] [6-19] [5-21] 
Vitamin A (RE) 1753 1734 1570 1161 
[305-3934] [565-3065] [698-5107] [656-2238] 
LP/LI =low phytate, low isoflavone; NP/LI =normal phytate, law isoflavone; 
LP/NI =low phytate, normal isoflavone; NP/NI =normal phytate, normal isoflavone 
*Selected nutrients assessed using Food Frequency Questionnaire (Block Dietary Data 
Systems} 
There were no significant differences for any of these characteristics at baseline among 
the treatment groups 
59 
TABLE 2 
Oxidative stress measures at baseline and 6 weeks (Mean f SD) 
Treatment Time PC PGF2Q oxLDL 
(pmoUmg) (pg/ml) (U/L) 
LPiLI Base 204 ~ 54 4118 ~ 573a 66.4 ~ 15.9 
Post 196 ~ 49 3978 ~ 654 62.2 ~ 17.9 
Difference+ -9 ~ 31 -139 ~ 653 -4.2 ~ 9.2 
NP/LI Base 197 ~ 55 5327 ~ 1782b 81.0 ~ 25.3 
Post 181 ~ 40 5000 ~ 1200 76.6 ~ 24.4 
Difference+ -16 ~ 29 -327 ~ 1397 -4.3 ~ 17.6 
LP/NI Base 183 ~ 39 4471 ~ 1183ab 77.9 ~ 29.4 
Post 185 ~ 42 42$6 ~ 1040 67.9 ~ 18.8 
Difference+ 2 ~ 31 -186 ~ 893 -10.0 ~ 17.5 
NP/NI Base 190 ~ 3 5 4678 ~ 13 66ab 75.1 ~ 21.4 
Post 178 ~ 43 4411 ~ 992 69.3 ~ 24.0 
Difference+ -12 ~ 24 -207 ~ 63 7 -5.9 ~ 18.5 
LP1LI =low phytate, low isoflavone; NPILI =normal phytate, low isoflavone; LP/NI = 
low phytate, normal isoflavone; NP/NI =normal phytate, normal isoflavone 
PC =protein carbonyls; oxLDL =oxidized low-density lipoproteins; PGF2a = 8-iso-prostglandin- 
Fla 
+Mean difference (week 6 -Baseline} 
~,b,ab Superscripts refer to differences among the treatments for the same time point 
Baseline values among the treatments were not different except for PGF2a
Differences from baseline to week-6 for each treatment were not significant 
60 
TABLE 3 
Blood lipid measures at baseline and 6 weeks (Mean f SD) 
3'~ LDL-C HDL-C TG 
(mg/dL) (mg/dL) (mg/dL) (mg/dL) 
LPfLI Base 223 X31 138 X27 63 ~17ab 112 ~69a
host 215 X33 129 X29 65 ~ 14 101 ~5 ~ 
Difference+ -8 ~ 18 -9 ~ 19 3 ~7 -11 X47 
NPiLI Base 225 X31 139 X32 53 ~ 10b 168 ~95b
Post 221 X36 135 X28 53 X10 167 X77 
Difference+ -4 X31 -4 X33 1 ~6 -1 X56 
LP/NI Base 227 X35 144 X30 62 ~13ab 104 ~43a
Post 213 X30 131 X27 59 ~ 14 117 X63 
Difference -14 X23 * -14 ~ 16* * -3 ~9 12 X32 
NP/NI Base 23 5 X40 151 ~3 8 65 =~ 11 a 1 OO X51 a 
Post 220 X38 134 X36 64 X14 106 X77 
Difference+ -16 X20* -16 ~ 16 * * -1 ~7 7 X39 
LPILI =low phytate, low isoflavone; NPCLI =normal phytate, low isoflavone; 
LP/NI =low phytate, normal isoflavone; NP/NI =normal phytate, normal 
isoflavone 
T~ =total cholesterol; LDL-C =low-density lipoprotein; HDL-C = high-density 
lipoprotein; TG = triacylglycerol 
+Mean difference (week 6 -Baseline) 
a,bDab Superscripts refer to the differences among the treatments for the same time 
point 
* p<0.05, * * p<0.01, * * * p<0.005 
Baseline values among the treatments were not different except for HDL-C and 
TG 
There was a significant decrease from baseline to week-6 in the LP/NI and 
NP/NI groups far T~ and LDL-C 
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TABLE 4 
Intercorrelations of baseline values [correlation coefficient (p-value)] 
PGF2a oxLDL TC LDL-C HDL-C TG BMI 
PC 0.15 0.12 0.03 -0.05 0.00 0.18 0.10 
PGF2a 0.25 0.17 0.04 -0.44 a.74d 0.3 3 
a 
oxLDL 0.614 0.624 -0.32a 0.39b 0.34a
TC 0.944 0.07 0.20 0.14 
LDL-C -0.06 0.05 0.17 
HDL-C -0.65 -0.524
TG 0.45 
LP/LI =low phytate, low isoflavone; NP/LI =normal phytate, low isoflavone; LP/NI =low 
phytate, normal isoflavone; NF/NI =normal phytate, normal isoflavone 
TC =total cholesterol; LDL-C =low-density lipoprotein; HDL-C = high-density lipoprotein; 
TG = triacylglycerol 
PC =protein carbonyls; oxLDL =oxidized low-density lipoproteins; PGF2a = 8-iso-
prostglandin-F2a
a p<0.05 
b p<0.01 
p<0.001 
d p<0.0001 
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Figure l: Percent Change in Oxidative Stress Indices 
A B 
C 
PC 
1 
_fip_ 
LP/Lt NP/L{ LP/N1 NP/NI 
oxLDL 
LP/Ll NP/LI LP/N~ NP/NI 
a.o 
-25-
a~ 
,~ -5.0-
V 
0 
-7 5~ 
w10.0 
~GF2a 
LP/LI NPILf LP/NI NP/NI 
Panel A =protein carbonyls (PC), Panel 8 = 8-iso-prostglandin-F2a (POFZa)~ 
Panel C =oxidized low-density lipoproteins (oxLDL) 
%Change =[(Post-Base)/Base~ ~ I00 
Percent change among the treatments are not significantly different for any of the 
indices. 
~~ 
TC 
Figure 2: Percent Change in Blood Lipids 
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Figure 3: Contrast Coding for oxidative Stress Indices 
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Figure 4: Contrast Coding for Blood Lipids Measures 
A B 
TC 
C 
LP 
l 
NP 
T 
I-DL-C 
L1 NI 
-2- 
~a
~~ LP NP LI NI 
LDL-G 
Panel A =- total cholesterol (TC), Panel B =low-density lipoprotein cholesterol (LDL-C), 
Panel C = high-density lipoprotein cholesterol (HDI.~-C) 
LP = LP/LI and LP1NI, NP = NP/LI and NPiNI, LI = LP/LI and NP/LI, 
NI = LPINI and NP/NI 
*p=0.1623, * *p=0.1477, * ~ gyp-=0.0991 
There was no significant difference for either of the contrasts (LP vs NP or LI vs NI) for 
all of the indices, based on contrast coding. 
66 
GEl'~ERA~ ~ONCi~ITSIOI~TS 
In summary, the results of this study suggest that soy protein containing normal 
isoflavone amounts have a moderate effect on reducing blood. lipid. concentrations and 
oxidative stress indices. However, the changes elicited by the isoflavones were not 
significant, suggest there may be other soy components responsible for the lipid-lowering 
and antioxidant effects of soy. It may also be that isoflavones have an additive effect with 
soy protein and/or other constituents rather than an individually effect. Phytate elicited 
similar results on oxidative stress indices, causing only marginal reductions with no 
significant difference. with regard to blood lipids, though, phy~tate had no effect. 
The sample size in this study may have been too small to obtain significant effects, 
thus recruiting a larger number of subjects may be beneficial in future research. Also, future 
studies should increase the time of intervention in order to test sustainability of the results. 
